Sign In
Buy IMNN
$2.10
-0.0400 (-1.87%)
At Close: Jun 03, 2026
Celsion Corporation (CLSN) CEO Michael Tardugno on Q2 2020 Results - Earnings Call Transcript
04:24pm, Friday, 14'th Aug 2020
Celsion Corporation (NASDAQ:CLSN) Q2 2020 Results Conference Call August 14, 2020 11:00 AM ET Company Participants Kim Golodetz - IR, LHA Investor Relations Michael Tardugno - Chairman, President and
Celsion: Q2 Earnings Insights
12:48pm, Friday, 14'th Aug 2020
Shares of Celsion (NASDAQ:CLSN) rose 2% in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share were up 37.93% year over year to ($0.18), which missed the esti
Celsion Corporation Reports Second Quarter 2020 Financial Results and Provides Business Update
12:00pm, Friday, 14'th Aug 2020
Initiates Promising Phase II Study of GEN-1 in Advanced Ovarian Cancer Will Continue Following Patients in Phase III OPTIMA Study for Overall Survival; Data Maturity at Issue Conference Call Begins T
Celsion Corporation to Hold Second Quarter 2020 Financial Results and Business Update Conference Call on Friday, August 14, 2020
12:30pm, Friday, 07'th Aug 2020
LAWRENCEVILLE, N.J, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the second quarte
Celsion Corporation to Continue Following Patients in Phase III OPTIMA Study for Overall Survival
12:30pm, Tuesday, 04'th Aug 2020
Ongoing Analysis of Unblinded Study Data Suggests Data Maturity May be at Issue Cohort of 26 Consecutive Patient Deaths Differs Substantially from Predicted Behavior and from the Balance of the Trial
Celsion Trial Progress, And Other News: The Good, Bad And Ugly Of Biopharma
03:53pm, Tuesday, 28'th Jul 2020
Celsion advances Phase II advanced ovarian cancer trial. Zentalis inks clinical collaboration with Eli Lilly.
Celsion Corporation Initiates Phase II OVATION 2 Study of GEN-1 in Advanced Ovarian Cancer
12:30pm, Monday, 27'th Jul 2020
Promising Translational and Clinical Findings Support the Randomized Trial in Newly Diagnosed Patients Non-Viral Nanoparticle Delivery System, TheraPlas Platform, Demonstrates Potential for Long-Ter
Is the Options Market Predicting a Spike in Celsion (CLSN) Stock?
12:56pm, Tuesday, 21'st Jul 2020
Investors need to pay close attention to Celsion (CLSN) stock based on the movements in the options market lately.
Celsion (CLSN) Stock Loses a Wall Street Supporter
02:26am, Saturday, 18'th Jul 2020
Stocks go up, stocks go down, you can't explain that...Or maybe you can, if the stock happen to be a biotech that just flunked a clinical trial. Which leads us nicely to Celsion Corporation (CLSN).
Celsion Down on DMC Recommendation to Stop Liver Cancer Study
02:49pm, Tuesday, 14'th Jul 2020
Celsion (CLSN) plummets on DMC recommendation to stop its phase III study assessing the efficacy of ThermoDox for HCC.
Celsion Corporation to Hold Conference Call to Discuss OPTIMA Study on Wednesday, July 15, 2020 at 11:00 a.m. Eastern Time
12:30pm, Tuesday, 14'th Jul 2020
LAWRENCEVILLE, N.J., July 14, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) will host a conference call and webcast on Wednesday, July 15 at 11:00 a.m. Eastern time to discuss its curren
Recommendation Based on DMC’s Finding Following the Second Pre-Planned Interim Analysis that the OPTIMA Study is Unlikely to Meet its Primary Efficacy Endpoint of Overall.
U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.04%
12:00am, Monday, 13'th Jul 2020
U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.04%
Edited Transcript of CLSN earnings conference call or presentation 15-May-20 3:00pm GMT
12:18am, Sunday, 28'th Jun 2020
Q1 2020 Celsion Corp Earnings Call
Celsion (NASDAQ:CLSN) Rating Reiterated by Dawson James
05:56am, Friday, 26'th Jun 2020
Celsion (NASDAQ:CLSN)‘s stock had its “buy” rating restated by equities research analysts at Dawson James in a report issued on Wednesday, AnalystRatings.com reports. They presently have a $4.00
